Pharma's Market

SPECIAL REPORT

Healthy Horizons
A brand new series of weekly segments which will explore the macro and micro issues facing the global economy.

LATEST FROM OUR BLOGS

» More

- 5 Stocks That Benefit from Health Care Legislation: Analysts

MORE HEADLINES

» Markets | Economy | Companies

- Tuesday's Heavy Dose of Data to Dictate 'Risk' Behavior

PHARMA'S MARKET VIDEO

» More

Cholesterol Drug Battle: Niaspan vs. Zetia 16 Nov 2009
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.

Cardiologist Grades Cholesterol Drug Study

16 Nov 2009

Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Dr. Steven Nissen, chairman of the Department of Cardiovascular Medicine at The Cleveland Clinic, shares his reaction with CNBC's Mike Huckman.

Merck's Cholesterol Drugs Under Pressure

16 Nov 2009

A new study is putting Merck's cholesterol drugs under pressure today, reports CNBC's Mike Huckman, with Ken Frazier, Merck Global Human Health president.

Cholesterol Drug Battle: Merck vs. Abbott Labs

16 Nov 2009

Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Barbara Ryan, pharma analyst at Deutsche Bank Securities, shares her reaction.

Cholesterol Drug Battle 16 Nov 2009
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.

Novo Nordisk CEO on Diabetes Epidemic

13 Nov 2009

Diabetes is a global epidemic that presents an estimated $25 billion drug and device market and some predict that number could double over the next several years. Lars Sorensen, CEO of Novo Nordisk, the world's largest diabetes care company, talks to CNBC's Mike Huckman.

RSS FEED

» Help

Subscribe to this RSS feed
Stay up to date with Pharma's Market.

CNBC ON DIGG

Lights, Camera, Lipitor!

Published: Tuesday, 3 Nov 2009 | 1:46 PM ET

Text Size

By: Mike Huckman
CNBC Correspondent

Maybe it's time for a career change.

I don't know where or how they found it, but "The In Vivo Blog" came across a great little nugget today.

Pfizer [PFE Loading... () ], or one of its ad agencies, is apparently putting out a casting call for a new Lipitor pitchman. Call my agent!

In Vivo says the posting is calling for, among other things, 50-65-year-old men of all ethnicities who've been on Lipitor for at least six months and a fresh face.

I've been on 10 mg of Lipitor for several years. The problem is I'm not 50...yet. And, yeah, I'd have to give up my day job to become a drug pitchman. Although maybe Pfizer would lower the age requirement so it could tout the fact that CNBC's former pharmaceuticals reporter likes his Lipitor.

(My tongue is in my cheek.)

I also went off of the drug for awhile earlier this year when I had some chronic shoulder muscle pain, but after a several acupuncture treatments, it eventually went away and now I'm back on Lipitor.

Imagine the exposure. Lipitor commercials and print ads are ubiquitous. Pfizer has about two years left to hawk Lipitor before it goes generic. So, here's your chance at stardom. Just as long as they don't make you sing some silly song like "Viva Viagra!" and look happy about it.

Questions? Comments? and follow me on Twitter at mhuckman